Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 901–1,000 of 1,000
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma
Mendeville, M., Janssen, J., Kim, Y., van Dijk, E., de Jong, D., & Ylstra, B. (2022) · Leukemia · doi:10.1038/s41375-022-01670-6 · Cited by 13
Gao, H., Nuerlan, A., Abulajiang, G., Cui, W., Xue, J., Sang, W., Li, S.-J., Niu, J., Ma, Z., Zhang, W., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152528 · Cited by 13
Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma
Roh, J., Jung, J., Lee, Y., Kim, S., Pak, H.-K., Lee, A.-N., Lee, J. H., Cho, J., Cho, H., Yoon, D. H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00329 · Cited by 13
Derenzini, E., Mazzara, S., Melle, F., Motta, G., Fabbri, M., Bruna, R., Agostinelli, C., Cesano, A., Corsini, C. A., Chen, N., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.236455 · Cited by 13
Boiza‐Sánchez, M., Manso, R., Balagué, O., Chamizo, C., Askari, E., Salgado, R., Blas, C., Aguirregoicoa-García, E., Menárguez, J., Santonja, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241634 · Cited by 13
Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom
Roschewski, M. J. (2021) · Haematologica · doi:10.3324/haematol.2020.266635 · Cited by 13
Slack, G. W. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.01.010 · Cited by 12
Wang, N., Chen, F.-L., Lu, P., Teng, Y., Wei, X., Guo, H., Jiang, X.-M., Huang, L., Liu, S., Liang, Z., et al. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i12.606 · Cited by 12
Wu, Y., Yuan, Q., Shen, H., Du, K., Shang, C., Li, Y., Zhang, X., Wu, J., Gao, R., Wang, L., et al. (2024) · Cancer Science · doi:10.1111/cas.16377 · Cited by 12
Self-citationDiehl, C., Soberón, V., Baygün, S., Chu, Y., Mandelbaum, J., Kraus, L., Engleitner, T., Rudelius, M., Fangazio, M., Daniel, C., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.11.023 · Cited by 12
Coyle, K. M., Dreval, K., Hodson, D. J., & Morin, R. D. (2025) · Blood Advances · doi:10.1182/bloodadvances.2022009461 · Cited by 12
Self-citationEpigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment
Gheorghe, A. D., Cristian, M., Calin, E., Pricop, A.-R., Mociu, S.-I., Seicaru, L., Deacu, S., Ciufu, N., Suceveanu, A., Suceveanu, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13040853 · Cited by 12
Jin, Y., Wang, Y., Wang, L., Zhang, H., Ren, B., Zheng, J., Xia, Q., & Liu, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1550207 · Cited by 12
Varano, G., Lonardi, S., Sindaco, P., Pietrini, I., Morello, G., Balzarini, P., Vit, F., Neuman, H., Bertolazzi, G., Brambillasca, S., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0099 · Cited by 12
Self-citationComputational study on novel natural inhibitors targeting BCL2
Lv, X., Jiang, Y., Wang, X., Xie, H., Dou, G., Wang, J., Yang, W., Wang, H., Li, Z., Zhang, X., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01513-x · Cited by 12
Self-citationWight, J. C., Hamad, N., Campbell, B. A., Ku, M., Lee, K. M. L., Rose, H. L., Armytage, T., Latimer, M., Lee, H., Lee, S. T., et al. (2021) · Internal Medicine Journal · doi:10.1111/imj.15533 · Cited by 12
Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes
Andrades, Á., Álvarez-Pérez, J. C., Patiño-Mercau, J. R., Cuadros, M., Baliñas-Gavira, C., & Medina, P. P. (2022) · Blood · doi:10.1182/blood.2021011708 · Cited by 12
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
Jakša, R., Karolová, J., Svatoň, M., Kazantsev, D., Grajciarová, M., Pokorná, E., Tonar, Z., Klánová, M., Winkowska, L., Maláriková, D., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00784-w · Cited by 12
Yan, W., Shi, X., Wang, H., Liao, A., & Yang, W. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03476-7 · Cited by 12
Rapier-Sharman, N., Clancy, J., & Pickett, B. E. (2022) · Journal of Bioinformatics and Systems Biology · doi:10.26502/jbsb.5107040 · Cited by 12
Treiber, H., Nilius‐Eliliwi, V., Seifert, N., Vangala, D., Wang, M., Seidel, S., Mika, T., Marschner, D., Zeremski, V., Wurm‐Kuczera, R., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000926 · Cited by 12
Niiyama‐Uchibori, Y., Okamoto, H., Miyashita, A., Mizuhara, K., Kawaji‐Kanayama, Y., Fujino, T., Tsukamoto, T., Mizutani, S., Shimura, Y., Teramukai, S., et al. (2024) · Hematological Oncology · doi:10.1002/hon.3252 · Cited by 12
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
Pirosa, M. C., Stathis, A., & Zucca, E. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2309701 · Cited by 12
Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients
Bagratuni, T., Aktypi, F. D., Theologi, O., Σάκκου, Μ., Verrou, K., Mavrianou‐Koutsoukou, N., Patseas, D., Liacos, C., Skourti, S., Papadimou, A., et al. (2024) · HemaSphere · doi:10.1002/hem3.27 · Cited by 12
Subverting the Canon: Novel Cancer-Promoting Functions and Mechanisms for snoRNAs
Huo, M., Kumar, S., Nakatsu, K., Deng, Y., & Jijiwa, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052923 · Cited by 12
Park, C., Lee, H. S., Kang, K., Lee, W.-S., Do, Y. R., Kwak, J., Shin, H., Kim, S., Yi, J. H., Lim, S.-N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47198-4 · Cited by 12
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma
Portelinha, A., Wang, S., Parsa, S., Jiang, M., Gorelick, A. N., Mohanty, S., Sharma, S., de Stanchina, E., Berishaj, M., Zhao, C., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231143 · Cited by 12
Xiao, R., Zhao, W., Lin, W., Xiao, Y., Ren, J., Zhou, Y., Meng, W., Bi, E., & Jiang, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009212 · Cited by 12
Gao, Y., Ping, L., Shan, C., Huang, H., Li, Z., Zhou, H., Lai, M., Cai, L., Bai, B., Huang, C., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0156 · Cited by 12
Pomeroy, A. E., & Palmer, A. C. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0230 · Cited by 12
Gormsen, L. C., Vendelbo, M. H., Pedersen, M. A., Haraldsen, A., Hjorthaug, K., Bogsrud, T. V., Petersen, L. J., Jensen, K. J., Brøndum, R. F., & El‐Galaly, T. C. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0503-z · Cited by 12
EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B‐cell lymphoma
Filho, E. H. N., Hirth, C. G., Frederico, I. A., Burbano, R. M. R., Carneiro, T. X., & Rabenhorst, S. H. B. (2020) · Apmis · doi:10.1111/apm.13029 · Cited by 12
Therapeutic vaccines for aggressive B-cell lymphoma
Xu-Monette, Z. Y., & Young, K. H. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1805113 · Cited by 12
Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo, G., Marchesi, F., Spagnuolo, M., Méndez, A. B. D., Masi, S., Mengarelli, A., & Rizzo, M. G. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100776 · Cited by 12
Ahmed, S., Glover, P., Taylor, J., Sha, C., Care, M. A., Tooze, R. M., Davies, A. J., Westhead, D. R., Johnson, P., Burton, C. H., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17246 · Cited by 12
Sorting biologic subtypes of primary CNS lymphoma
Roschewski, M. J., & Phelan, J. D. (2021) · Blood · doi:10.1182/blood.2020009968 · Cited by 12
Self-citationTUC338 Promotes Diffuse Large B Cell Lymphoma Growth via Regulating EGFR/PI3K/AKT Signaling Pathway
Li, Y., Jia, Z., Zhao, H., Liu, X., Luo, J., Cui, G.-R., & Kong, X. (2021) · Journal of Oncology · doi:10.1155/2021/5593720 · Cited by 12
Self-citationAdvances in Immunotherapy for Diffuse Large B Cell Lymphoma
Shouse, G., & Herrera, A. F. (2021) · BioDrugs · doi:10.1007/s40259-021-00491-w · Cited by 12
Advances in Lymphoma Molecular Diagnostics
Kos, I. A., Thurner, L., Bittenbring, J. T., Christofyllakis, K., & Kaddu‐Mulindwa, D. (2021) · Diagnostics · doi:10.3390/diagnostics11122174 · Cited by 12
Bastos‐Oreiro, M., Suárez‐González, J., Andrés-Zayas, C., Carrión, N. C., Moreno, S., Carbonell, D., Chicano, M., Muñiz, P., Sanz‐Villanueva, L., Diaz-Crespo, F. J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02362-4 · Cited by 12
Wang, J., Shen, K., Mu, W., Li, W., Zhang, M., Zhang, W., Li, Z., Ge, T., Zhu, Z., Zhang, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873789 · Cited by 12
Self-citationMolecular Diagnostic Testing for Hematopoietic Neoplasms
Hergott, C. A., & Kim, A. S. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.04.005 · Cited by 12
CD30 expression in a case of intravascular large B‐cell lymphoma, cutaneous variant
Provasi, M., Bagnoli, F., Fanoni, D., Violetti, S. A., Tomasini, D., & Berti, E. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13446 · Cited by 12
Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas
Harrop, S., Yannakou, C. K., van der Weyden, C., & Prince, H. M. (2022) · Hemato · doi:10.3390/hemato3010015 · Cited by 11
Ceribelli, M., Tosto, F. A., Zhang, X., Melani, C. J., Roschewski, M. J., Beck, E., Klumpp-Thomas, C., Peer, C. J., Wilson, K. M., Chen, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413372121 · Cited by 11
Self-citationXia, Y. Y., He, Q., Liu, D., Xie, L., Wang, H. Z., Chen, C., Zhao, C., Shan, N., Shi, S., Wei, H., et al. (2025) · Cancer · doi:10.1002/cncr.35697 · Cited by 11
An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models
Zhang, T., Beytullahoglu, O., Tulaiha, R., Luvisotto, A., Szczepanski, A. P., Tsuboyama, N., Zhao, Z., & Wang, L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci179703 · Cited by 11
Phina-Ziebin, X., Bachy, E., Gros, F., Blasi, R. D., Herbaux, C., Bay, J. O., Carras, S., Bories, P., Casasnovas, O., Jardin, F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014732 · Cited by 11
Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9
Guo, R., Sun, Y., Lim, M. Y., Shah, H., Paulo, J. A., Ahmed, R. A., Li, W., Zhang, Y., Yang, H., Wang, L. W., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186258 · Cited by 11
Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology
Das, K., Samol, J., Khan, I. S., Ho, B. C. S., & Chuah, K. L. (2026) · Cancers · doi:10.3390/cancers18020327 · Cited by 11
Collins, G. P., Clevenger, T. N., Burke, K. A., Buyue, Y., MacDonald, A., Cunningham, D., Fox, C. P., Goy, A. H., Gribben, J. G., Nowakowski, G. S., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1938027 · Cited by 11
Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
Weissinger, S. E., Dugge, R., Disch, M., Barth, T. F. E., Bloehdorn, J., Zahn, M., Marienfeld, R. B., Viardot, A., & Mӧller, P. (2022) · eJHaem · doi:10.1002/jha2.428 · Cited by 11
Guan, T., Zhang, M., Liu, X., Li, J., Xin, B., Ren, Y., Yang, Y., Wang, H., Zhao, M., Huang, Y.-P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1003957 · Cited by 11
Self-citationHaider, Z., Wästerlid, T., Spångberg, L. D., Rabbani, L., Jylhä, C., Þorvaldsdóttir, B., Skaftason, A., Awier, H. N., Krstić, A., Gellerbring, A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176698 · Cited by 11
Next generation sequencing in routine diagnostics of mature non‐Hodgkin 's B‐cell lymphomas
Breinholt, M. F., Schejbel, L., Gang, A. O., Nielsen, T. H., Pedersen, L. M., Høgdall, E. V. S., & Nørgaard, P. H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14048 · Cited by 11
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Lou, N., Wang, G., Wang, Y., Xu, M., Zhou, Y. L., Tan, Q., Zhong, Q., Zhang, L., Zhang, X., Liu, S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100625 · Cited by 11
Self-citationPrognostic value of whole-body dynamic 18F-FDG PET/CT Patlak in diffuse large B-cell lymphoma
Yin, J., Wang, H., Zhu, G., Chen, N., Khan, M. I., & Zhao, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19749 · Cited by 11
Self-citationCox, M. C., Esposito, F., Postorino, M., Venditti, A., & Napoli, A. D. (2023) · Cancers · doi:10.3390/cancers15184440 · Cited by 11
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells
Feng, Q., Hu, K., Hu, H., Lu, Y., Zhang, H., Wang, G., Zhang, Q., Xu, Z., Gao, X., Jia, X., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111139 · Cited by 11
Li, L., Yang, W., Pan, Y., Ye, R., Wang, Y., Li, S., Jiang, H., Zhang, Q., Wang, X., & Yan, J. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2328227 · Cited by 11
Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma
Yuan, X., Guan, D., Chen, C., Guo, S., Wu, H., Bu, H., Yang, C., Wang, M., Zhou, J., & Zhang, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02008 · Cited by 11
Sarkozy, C., Molina, T. J., Dubois, S., Portugues, C., Bohers, É., Ysebaert, L., Houot, R., Pica, G. M., Ruminy, P., Herbaux, C., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103157 · Cited by 11
Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region
Ayers, A. A., Lyu, L., Dance, K. V., Ward, K. C., Flowers, C. R., Koff, J. L., & McCullough, L. E. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.06.009 · Cited by 11
Hu, B., Nastoupil, L. J., Loghavi, S., Westin, J. R., Thakral, B., Fayad, L., Hagemeister, F. B., Neelapu, S. S., Samaniego, F., Lee, H. J., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1663418 · Cited by 11
Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas
Sorigué, M., Santos-Gómez, M., Comes, M., Raya, M., Vergara, S., Tapia, G., Navarro, J., Morales‐Indiano, C., & Juncà, J. (2019) · Laboratory Medicine · doi:10.1093/labmed/lmz085 · Cited by 11
Carr, M., Mamand, S., Chapman, K. L., Perrior, T. R., & Wagner, S. D. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15774 · Cited by 11
IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3
Petrenko, O., Li, J., Cimica, V., Mena, P., Shin, H. Y., D’Amico, S., & Reich, N. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247394 · Cited by 11
Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets
Yoshida, N., Miyoshi, H., & Ohshima, K. (2021) · Cancers · doi:10.3390/cancers13081801 · Cited by 11
Sadeghi, L., & Wright, A. P. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126247 · Cited by 11
Bouzidi, A., Labrèche, K., Baron, M., Veyri, M., Denis, J. A., Touat, M., Sanson, M., Davi, F., Guillerm, E., Jouannet, S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.661272 · Cited by 11
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma
Mondello, P., & Ansell, S. M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.007 · Cited by 11
Shared and distinct genetic features in human and canine B-cell lymphomas
Coyle, K. M., Hillman, T., Cheung, M. C., Grande, B. M., Bushell, K. R., Arthur, S. E., Alcaide, M., Thomas, N., Dreval, K., Wong, S. K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006429 · Cited by 11
Primary CNS lymphoma: update on molecular pathogenesis and therapy
Mo, S. S., Cleveland, J. C., & Rubenstein, J. L. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133541 · Cited by 11
de Jonge, A. V., van Werkhoven, E. D., Dinmohamed, A. G., Nijland, M., Zwinderman, A. H., Bossuyt, P. M., Veldhuis, M. S., Rutten, E. G. G. M., Mous, R., Vermaat, J. S. P., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00854-2 · Cited by 11
Locus-specific human endogenous retroviruses reveal lymphoma subtypes
Singh, B., Dopkins, N., Fei, T., Marston, J. L., Michael, S., Reyes-Gopar, H., Curty, G., Heymann, J. J., Chadburn, A., Martin, P., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112541 · Cited by 11
Cell death in cancer in the era of precision medicine
Raschellà, G., Melino, G., & Gambacurta, A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0048-6 · Cited by 11
A T Cell-B Cell Tumor-Suppressive Axis in the Germinal Center
Kennedy, R., & Klein, U. (2019) · Immunity · doi:10.1016/j.immuni.2019.07.006 · Cited by 11
Taylor, J., Yeomans, A., & Packham, G. K. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00002 · Cited by 11
Orgueira, A. M., Arías, J. Á. D., López, M. C., Raíndo, A. P., García, A. L., García, R. A., González, M. S., Rodríguez, B. A., Santos, C. A., Pérez‐Encinas, M., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000706 · Cited by 11
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaPreprint
Ma, M. C. J., Tadros, S., Bouska, A. C., Heavican, T., Yang, H., Deng, Q., Moore, D., Akhter, A., Hartert, K., Jain, N., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/674259 · Cited by 11
Xist Repeat A coordinates an assembly of SR proteins to recruit SPEN and induce gene silencingPreprint
Trotman, J. B., Porrello, A., Schactler, S. A., DeLeon, L. E., Eberhard, Q. E., Boyson, S. P., Zhang, Z., Li, S., Lee, D. M., Kirik, S. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.21.655143 · Cited by 11
Yu, C., Shen, Q. “., Holmes, A. B., Mo, T., Tosato, A., Soni, R. K., Corinaldesi, C., Koul, S., Pasqualucci, L., Hussein, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51644-8 · Cited by 10
Suzuki, T., Fujii, K., Matsunaga, N., Sasaki, H., Kanamori, T., Asano, A. T., Kinoshita, S., Narita, T., Masaki, A., Sanda, T., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20099 · Cited by 10
Rao, J., Lin, X., Li, Q., Ma, N., Li, X., Li, J., Zhu, L., Zhao, P., Zeng, Y., Zhou, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01267-z · Cited by 10
Yamaguchi, S., Isokawa, T., Matsui, N., Kamiura, N., & Tsuruyama, T. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf137 · Cited by 10
Lou, N., Dai, L., Gao, R., Yang, J., Gui, L., Yang, S., Liu, P., Shi, Y., & Xiao-hong, H. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2849-2 · Cited by 10
Wang, Z., Feng, S., Yao, X., Zhao, R., Li, Y., Zheng, M., Li, Z., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1620895 · Cited by 10
Arnason, J. E., Matasar, M. J., Luminari, S., Tucker, D. L., Sun, D., Tao, W., Zhu, Y. O., Kundu, K., Gupta, N. T., Leary, A. Y., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016332 · Cited by 10
Genomic landscape and molecular subtypes of primary central nervous system lymphoma
Li, S., Li, D., Xia, Z., Wu, J., Ren, J. T., Li, Y., Cao, J., Sun, Y., Zhang, L., Ye, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01421-7 · Cited by 10
Current treatment algorithm: diffuse large B cell lymphoma
Ansell, S. M., & Nowakowski, G. S. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01458-2 · Cited by 10
Molecular Diagnostics of Non-Hodgkin Lymphoma
Solomon, J. P., & Arcila, M. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000447 · Cited by 10
Genomics of diffuse large B cell lymphoma
Koh, Y. (2021) · Blood Research · doi:10.5045/br.2021.2021049 · Cited by 10
Preston, S. E. J., Émond, A., Pettersson, F., Dupéré-Richer, D., Abraham, M. J., Riva, A., Kinal, M., Rys, R. N., Johnson, N. A., Mann, K. K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0216 · Cited by 10
Li, Z., Duan, Y., Ke, Q., Wang, M., Cen, H., & Zhu, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000460 · Cited by 10
Liu, X., Zhao, X., Yang, H. J., Wang, H., Piao, Y., & Wang, L. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13895 · Cited by 10
Self-citationBakhshi, T. J., Way, T., Muncy, B. C., & Georgel, P. T. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0288 · Cited by 10
Wang, J., Peng, H., Zhang, G., & Yan, W. (2023) · Hematology · doi:10.1080/16078454.2023.2198862 · Cited by 10
Self-citationEpigenetic targets in B- and T-cell lymphomas: latest developments
Ribeiro, M. L., Sánchez-Vinces, S., Mondragón, L., & Roué, G. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231173485 · Cited by 10
Agostinelli, C., Morandi, L., Righi, S., Cirillo, L., Iommi, M., Tonon, C., Mazzatenta, D., Zoli, M., Rossi, M., Bagnato, G., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100323 · Cited by 10
Białopiotrowicz, E., Noyszewska‐Kania, M., Jabłońska, E., Sewastianik, T., Komar, D. N., Debek, S. M., Garbicz, F., Wojtas, M., Szydłowski, M., Polak, A., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06186-0 · Cited by 10
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.